Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 PatientsF. Herms, Nicole Basset‐Séguin, Laurent Mortier et al.|Journal of Clinical Oncology|2019Cited by 69
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Alexander C. J. van Akkooi, Michal Kiciński et al.|The Lancet Oncology|2025Cited by 10
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational studyS. Monestier, Stéphane Dalle, Laurent Mortier et al.|International Journal of Cancer|2021Cited by 9
Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: A retrospective multicentric French study.F. Herms, Nicole Basset‐Séguin, Luc Haudebourg et al.|Journal of Clinical Oncology|2017Cited by 7
Fréquence des résistances au vismodegib dans une série de 207 patients atteints de carcinomes basocellulaires localement avancésN. Basset Seguin, Brigitte Dréno, Nicolas Poulalhon et al.|Annales de Dermatologie et de Vénéréologie|2016Cited by 2